The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines

Inclusion Criteria : Filter period: The subjects to receive first 10mcg recombinant hepatitis B vaccines: * Healthy subjects aged 16 and older as established by medical history and clinical examination * The subjects or their guardians are able to understand and sign the informed consent * Had never received the hepatitis B vaccines * Subjects who can and will comply with the requirements of the protocol Revaccination period: The nonresponders to receive first 60mcg recombinant hepatitis B vaccines: * Healthy subjects aged 16 and older as established by medical history and clinical examination * The subjects or their guardians are able to understand and sign the informed consent * After the routine administration of 10mcg hepatitis B vaccines, the peak period levels of anti-HBs is lower than 10mIU/ml * Subjects with temperature \<37.1°C on axillary setting * Subjects who can and will comply with the requirements of the protocol Exclusion Criteria: Filter period: The subjects to receive first 10mcg recombinant hepatitis B vaccines: * Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine * Family history of seizures or progressive neurological disease * Family history of congenital or hereditary immunodeficiency * Women of pregnancy, lactation or about to be pregnant in 60 days * Autoimmune disease or immunodeficiency * Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws * Any prior administration of administration of immunoglobulins Filter period: The subjects to receive second or/and third 10mcg recombinant hepatitis B vaccines: * Any reaction or hypersensitivity to the recombinant hepatitis B vaccines after the vaccinations * Serious adverse reactions to vaccines * Active infections * Subjects who want to quit the study * Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives Revaccination period: The nonresponders to receive first 60mcg recombinant hepatitis B vaccines: * Qualitative test of Anti-HBs, HBsAg or Anti-HBc on serum is positive * Any reaction or hypersensitivity to the recombinant hepatitis B vaccines after the vaccinations * Family history of seizures or progressive neurological disease * Family history of congenital or hereditary immunodeficiency * Women of pregnancy, lactation or about to be pregnant in 60 days * Autoimmune disease or immunodeficiency * Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws * Any prior administration of immunoglobulins, any other vaccines or experimental drugs in the last 7days * Any active infections and received any antibiotic or anti-virus treatments in the last 7 days * Had a fever in the last 3 days, with temperature ≥37.1°C * Participate in another clinical trials * Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives Revaccination period: The nonresponders to receive second or/and third 60mcg recombinant hepatitis B vaccines: * Any reaction or hypersensitivity to the recombinant hepatitis B vaccines after the vaccinations * Serious adverse reactions to vaccines * Active infections * Subjects who want to quit the study * Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives